DeepMed Research

The Gynecologic Oncology Group

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1970-01-01

Employees: 11

Market Cap: -

Website: http://www.gog.org

Clinical Trials

Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer

Not Applicable

Terminated

Conditions: Cervical Adenosquamous Carcinoma
Stage I Cervical Cancer
Cervical Adenocarcinoma
Cervical Squamous Cell Carcinoma

Interventions: Drug: Isosulfan Blue
Procedure: Lymph Node Mapping
Procedure: Lymphangiography
Drug: Methylene Blue
Procedure: Radionuclide Imaging
Procedure: Sentinel Lymph Node Biopsy
Radiation: Technetium Tc-99m Sulfur Colloid
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2003-10-07

Last Posted Date: 2017-11-06

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 102

Registration Number: NCT00070317

Locations: 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States

Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer

Phase 1

Completed

Conditions: Cervical Adenosquamous Carcinoma
Stage IIA Cervical Cancer
Stage IIB Cervical Cancer
Cervical Adenocarcinoma
Cervical Small Cell Carcinoma
Cervical Squamous Cell Carcinoma
Stage IB Cervical Cancer
Stage III Cervical Cancer
Stage IVA Cervical Cancer

Interventions: Drug: Gemcitabine Hydrochloride
Drug: Cisplatin
Radiation: Radiation Therapy
Radiation: Internal Radiation Therapy

First Posted Date: 2003-09-11

Last Posted Date: 2014-12-25

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 13

Registration Number: NCT00068549

Locations: 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States

Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Cancer of the Vulva

Phase 2

Completed

Conditions: Stage IVB Vulvar Cancer
Stage III Vulvar Cancer
Vulvar Squamous Cell Carcinoma

Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy
Drug: Cisplatin
Procedure: Conventional Surgery

First Posted Date: 2003-09-11

Last Posted Date: 2017-11-20

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 61

Registration Number: NCT00068406

Locations: 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
🇺🇸
Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio, United States
🇺🇸
Gynecologic Oncology of Indiana, Indianapolis, Indiana, United States

and more 100 locations

Combination Chemotherapy Compared With Hormone Therapy in Treating Patients With Recurrent, Stage III, or Stage IV Endometrial Cancer

Phase 3

Terminated

Conditions: Endometrial Cancer

First Posted Date: 2003-09-09

Last Posted Date: 2013-04-11

Lead Sponsor: Gynecologic Oncology Group

Registration Number: NCT00016341

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States
🇺🇸
Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States

and more 47 locations

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Cancer of the Vulva

Phase 3

Terminated

Conditions: Vulvar Cancer

First Posted Date: 2003-09-03

Last Posted Date: 2013-06-10

Lead Sponsor: Gynecologic Oncology Group

Registration Number: NCT00006096

Locations: 🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
🇺🇸
Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States

and more 27 locations

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer

Phase 2

Terminated

Conditions: Malignant Ovarian Mixed Epithelial Tumor
Ovarian Clear Cell Cystadenocarcinoma
Ovarian Endometrioid Adenocarcinoma
Ovarian Mucinous Cystadenocarcinoma
Ovarian Serous Cystadenocarcinoma
Primary Peritoneal Carcinoma
Stage III Ovarian Cancer
Undifferentiated Ovarian Carcinoma

Interventions: Drug: Carboplatin
Drug: Cyclophosphamide
Biological: Filgrastim
Drug: Paclitaxel
Procedure: Peripheral Blood Stem Cell Transplantation
Drug: Topotecan Hydrochloride

First Posted Date: 2003-08-25

Last Posted Date: 2017-08-09

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 12

Registration Number: NCT00004221

Locations: 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States

Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer

Phase 1

Completed

Conditions: Fallopian Tube Carcinoma
Primary Peritoneal Carcinoma
Recurrent Ovarian Carcinoma
Stage III Ovarian Cancer
Stage IV Ovarian Cancer

Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy
Drug: Chemosensitization/Potentiation Therapy
Drug: Docetaxel

First Posted Date: 2003-08-07

Last Posted Date: 2016-02-11

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 13

Registration Number: NCT00066456

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸
Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States

and more 4 locations

Quality of Life in Survivors of Gynecologic Cancer

Completed

Conditions: Endometrial Cancer
Ovarian Cancer

First Posted Date: 2003-07-18

Last Posted Date: 2013-05-27

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 311

Registration Number: NCT00003795

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States
🇺🇸
Ireland Cancer Center, Cleveland, Ohio, United States

and more 41 locations

Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer

Phase 1

Terminated

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer

First Posted Date: 2003-07-15

Last Posted Date: 2013-06-10

Lead Sponsor: Gynecologic Oncology Group

Registration Number: NCT00003382

Locations: 🇺🇸
Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Holden Comprehensive Cancer Center at The University of Iowa, Iowa City, Iowa, United States

and more 3 locations

Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix

Phase 3

Completed

Conditions: Cervical Adenocarcinoma
Cervical Adenosquamous Carcinoma
Cervical Squamous Cell Carcinoma
Recurrent Cervical Carcinoma
Stage IVB Cervical Cancer

Interventions: Drug: Cisplatin
Drug: Gemcitabine Hydrochloride
Drug: Paclitaxel
Other: Quality-of-Life Assessment
Drug: Topotecan Hydrochloride
Drug: Vinorelbine Tartrate

First Posted Date: 2003-07-09

Last Posted Date: 2018-10-17

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 513

Registration Number: NCT00064077

Locations: 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy